Upadacitinib with or without topical corticosteroids improves health-related quality of life in adolescent and adult patients with moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)

被引：0

作者：

Prajapati, Vimal H. ^{[1
,2
,3
,4
,5
,6
,7
]}

Rosmarin, David ^{[8
]}

Shumack, Stephen ^{[9
,10
,11
]}

Calimlim, Brian M. ^{[12
]}

Takemoto, Shunya ^{[10
]}

Hu, Xiaofei ^{[12
]}

Ladizinski, Barry ^{[12
]}

Warren, Richard B. ^{[13
]}

机构：

[1] Univ Calgary, Div Dermatol, Calgary, AB, Canada

[2] Univ Calgary, Dept Pediat, Sect Community Pediat, Calgary, AB, Canada

[3] Univ Calgary, Dept Pediat, Sect Pediat Rheumatol, Calgary, AB, Canada

[4] Univ Calgary, Dept Med, Calgary, AB, Canada

[5] Skin Hlth & Wellness Ctr, Calgary, AB, Canada

[6] Dermatol Res Inst, Calgary, AB, Canada

[7] Prob Med Res, Calgary, AB, Canada

[8] Tufts Med Ctr, Dept Dermatol, Boston, MA 02111 USA

[9] Univ Sydney, Sydney Med Sch Northern, Sydney, NSW, Australia

[10] Skin Hosp, Darlinghurst, NSW, Australia

[11] Royal North Shore Hosp Sydney, Sydney, NSW, Australia

[12] AbbVie Inc, N Chicago, IL USA

[13] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 187卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

174

引用

页码：E81 / E81

页数：1

共 50 条

[21] Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
Silverberg, Jonathan I.
Gooderham, Melinda J.
Paller, Amy S.
Deleuran, Mette
Bunick, Christopher G.
Gold, Linda F. Stein
Hijnen, Dirkjan
Calimlim, Brian M.
Lee, Wan-Ju
Teixeira, Henrique D.
Hu, Xiaofei
Zhang, Shiyu
Yang, Yang
Grada, Ayman
Platt, Andrew M.
Thaci, Diamant
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (03) : 485 - 496
[22] Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
Jonathan I. Silverberg
Melinda J. Gooderham
Amy S. Paller
Mette Deleuran
Christopher G. Bunick
Linda F. Stein Gold
DirkJan Hijnen
Brian M. Calimlim
Wan-Ju Lee
Henrique D. Teixeira
Xiaofei Hu
Shiyu Zhang
Yang Yang
Ayman Grada
Andrew M. Platt
Diamant Thaçi
American Journal of Clinical Dermatology, 2024, 25 : 485 - 496
[23] 413 Improvement in itch, symptoms and quality of life with upadacitinib through week 16 in adults and adolescents with atopic dermatitis: results from phase 3 studies (Measure Up 1, Measure Up 2 and AD Up)
Lio, Peter
Eichenfield, Lawrence F.
Marcoux, Danielle
Lee, Wan-Ju
Teixeira, Henrique D.
Raymundo, Eliza M.
Gamelli, Amy E.
Grada, Ayman
Hu, Xiaofei
Irvine, Alan D.
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[24] Ef-ficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD UpRandomized Clinical Trials
Paller, Amy. S.
JAMA DERMATOLOGY, 2024, 160 (05) : 582 - 582
[25] Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
Silverberg, Jonathan I.
Deleuran, Mette
Gold, Linda S.
Bunick, Christopher G.
Hijnen, Dirk Jan
Calimlim, Brian M.
Teixeira, Henrique D.
Platt, Andrew M.
Grada, Ayman
Hu, Xiaofei
Gooderham, Melinda
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB90 - AB90
[26] Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials
Simpson, Eric L.
Papp, Kim A.
Blauvelt, Andrew
Chu, Chia-Yu
Hong, H. Chih-Ho
Katoh, Norito
Calimlim, Brian M.
Thyssen, Jacob P.
Chiou, Albert S.
Bissonnette, Robert
Gold, Linda F. Stein
Wegzyn, Colleen
Hu, Xiaofei
Liu, Meng
Liu, John
Tenorio, Allan R.
Chu, Alvina D.
Guttman-Yassky, Emma
JAMA DERMATOLOGY, 2022, 158 (04) : 404 - 413
[27] Characterization of haematological and transaminase laboratory findings associated with upadacitinib use in moderate-to-severe atopic dermatitis: results of two phase III Trials (Measure Up 1 and 2)
Silverberg, J. I.
Gooderham, M. J.
de Bruin-Weller, M. S.
Papp, K. A.
Aoki, V.
Paller, A. S.
Ofori, S.
Tenorio, A. R.
Liu, Y.
Liu, J.
Chovatiya, Raj
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E168 - E169
[28] Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: results from two pivotal, phase III, randomized, double-blinded, monotherapy, placebo-controlled studies (Measure Up 1 and Measure Up 2)
Guttman-Yassky, E.
Teixeira, H. D.
Simpson, E. L.
Papp, K. A.
Pangan, A. L.
Blauvelt, A.
Thaci, D.
Chu, C. Y.
Hong, H. C.
Katoh, N.
Paller, A. S.
Calimlim, B.
Gu, Y.
Hu, X.
Liu, M.
Yang, Y.
Tenorio, A. R.
Chu, A. D.
Irvine, A. D.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E62 - E62
[29] Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) - results from two pivotal phase III studies (MEASURE UP 1 and MEASURE UP 2)
Simpson, E. L.
De Bruin-Weller, M. S.
Prajapati, V. H.
Calimlim, B. M.
Teixeira, H. D.
Zeng, J.
Liu, M.
Silverberg, J. I.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E124 - E124
[30] ABSOLUTE EASI TARGET IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF DATA FROM THE MEASURE UP 1 AND 2 STUDIES
Prajapatil, Vimal
Simpson, Eric L.
Thyssen, Jacob P.
Chovatiya, Raj
Lane, Michael
Teixeira, Henrique
Calimlim, Brian
Silverberg, Jonathan I.
ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 33 - 33

← 1 2 3 4 5 →